Clinical Trials | October 13, 2025
Roche to present latest cancer care data at ESMO 2025
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Merck will showcase results in innovative solutions in HIV treatment and prevention
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
Subscribe To Our Newsletter & Stay Updated
